Stéphane Doucet

419 total citations
12 papers, 34 citations indexed

About

Stéphane Doucet is a scholar working on Oncology, Pathology and Forensic Medicine and Epidemiology. According to data from OpenAlex, Stéphane Doucet has authored 12 papers receiving a total of 34 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Oncology, 5 papers in Pathology and Forensic Medicine and 4 papers in Epidemiology. Recurrent topics in Stéphane Doucet's work include Lymphoma Diagnosis and Treatment (5 papers), Viral-associated cancers and disorders (2 papers) and CNS Lymphoma Diagnosis and Treatment (2 papers). Stéphane Doucet is often cited by papers focused on Lymphoma Diagnosis and Treatment (5 papers), Viral-associated cancers and disorders (2 papers) and CNS Lymphoma Diagnosis and Treatment (2 papers). Stéphane Doucet collaborates with scholars based in Canada, United States and France. Stéphane Doucet's co-authors include Jeffrey Raizer, Priya Kumthekar, Dominic Martel, Isabelle Fleury, Valérie Martel‐Laferrière, Jean‐Philippe Adam, Aleksander Chudnovsky, Daniel P. Friedmann, Émilie Lemieux‐Blanchard and Josiane Bourré‐Tessier and has published in prestigious journals such as SHILAP Revista de lepidopterología, Blood and Supportive Care in Cancer.

In The Last Decade

Stéphane Doucet

11 papers receiving 34 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Stéphane Doucet Canada	4	17	14	13	10	5	12	34
Harold A. Sloas United States	4	19 1.1×	6 0.4×	23 1.8×	11 1.1×	4 0.8×	4	48
Felix Hinz Germany	3	16 0.9×	9 0.6×	19 1.5×	9 0.9×	3 0.6×	13	28
Srivalli Gopaluni United States	4	14 0.8×	9 0.6×	4 0.3×	9 0.9×	12 2.4×	8	35
Catherine Chassagne‐Clément France	2	31 1.8×	13 0.9×	6 0.5×	17 1.7×	2 0.4×	3	31
Nicole Lucas United States	2	21 1.2×	18 1.3×	7 0.5×	9 0.9×	9 1.8×	6	28
Sophy Denker Germany	4	23 1.4×	10 0.7×	3 0.2×	20 2.0×	5 1.0×	5	35
Susana Merino Spain	2	22 1.3×	8 0.6×	5 0.4×	5 0.5×	9 1.8×	3	43
Giulia Palazzo Italy	5	12 0.7×	11 0.8×	5 0.4×	16 1.6×	2 0.4×	6	36
Robert Galamaga United States	3	31 1.8×	6 0.4×	5 0.4×	23 2.3×	3 0.6×	5	39
Mónica Baile Spain	2	13 0.8×	5 0.4×	12 0.9×	10 1.0×	1 0.2×	8	21

Countries citing papers authored by Stéphane Doucet

Since Specialization

Citations

This map shows the geographic impact of Stéphane Doucet's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stéphane Doucet with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stéphane Doucet more than expected).

Fields of papers citing papers by Stéphane Doucet

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stéphane Doucet. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stéphane Doucet. The network helps show where Stéphane Doucet may publish in the future.

Co-authorship network of co-authors of Stéphane Doucet

This figure shows the co-authorship network connecting the top 25 collaborators of Stéphane Doucet. A scholar is included among the top collaborators of Stéphane Doucet based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stéphane Doucet. Stéphane Doucet is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

Assouline, Sarit, Amitkumar Mehta, Walter Hanel, et al.. (2025). Phase I/II Study of Subasumstat (TAK-981) in Combination With Rituximab in Relapsed/Refractory Non-Hodgkin Lymphoma. Clinical Lymphoma Myeloma & Leukemia. 25(11). 788–799.e11. 1 indexed citations

Adam, Jean‐Philippe, et al.. (2024). Impact of universal hepatitis B virus (HBV) screening using chemotherapy orders on the HBV reactivation in cancer patients. Supportive Care in Cancer. 32(8). 541–541. 3 indexed citations

Doucet, Stéphane, et al.. (2022). Expanding the spectrum of Epstein-Barr virus and human herpesvirus-8 co-infection associated large B-cell lymphomas with plasmablastic differentiation in HIV-positive patients: Report of two unusual cases and review of the literature. SHILAP Revista de lepidopterología. 29. 300657–300657. 1 indexed citations

Assouline, Sarit, Amitkumar Mehta, Tycel Phillips, et al.. (2021). TAK-981, a First-in-Class SUMO-Activating Enzyme Inhibitor, Combined with Rituximab in Adult Patients (Pts) with CD20-Positive Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL): Phase 1 Data. Blood. 138(Supplement 1). 2488–2488. 4 indexed citations

Adam, Jean‐Philippe, et al.. (2020). Risks of hepatitis C virus reactivation in a real-life population of oncology patients treated in an academic center. Journal of Oncology Pharmacy Practice. 27(8). 1815–1820. 1 indexed citations

Doucet, Stéphane, et al.. (2019). From theory to practice: implementing a standardized, interactive education session on oral anticancer medication (OAM) for patients and their caregivers. Supportive Care in Cancer. 28(8). 3897–3904.

Bourré‐Tessier, Josiane, et al.. (2019). Unusual presentation for small lymphocytic lymphoma: Case report of a man with bilateral ear involvement and review of the literature. European Annals of Otorhinolaryngology Head and Neck Diseases. 136(3). S45–S47. 2 indexed citations

Roy, Claudie, Jean‐Philippe Adam, Franck Morin, et al.. (2018). Azacitidine-Induced Pyoderma Gangrenosum at Injection Sites in a Patient with Myelodysplastic Syndrome. Current Oncology. 25(1). 103–105. 3 indexed citations

Fleury, Isabelle, et al.. (2017). Rituximab Maintenance for Two Years in Previously Untreated Follicular Lymphoma: No Difference in Outcome between Patients Receiving Treatment at Two Month Versus Three Month Interval. Blood. 130. 4064–4064. 1 indexed citations

10.

Kuruvilla, John, M. Crump, Diego Villa, et al.. (2017). CANADIAN CANCER TRIALS GROUP (CCTG) LY.17: A RANDOMIZED PHASE II STUDY EVALUATING NOVEL SALVAGE THERAPY PRE‐AUTOLOGOUS STEM CELL TRANSPLANT (ASCT) IN RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA (RR‐DLBCL) ‐ OUTCOME OF IBRUTINIB + R‐GDP. Hematological Oncology. 35(S2). 88–88. 5 indexed citations

11.

Doucet, Stéphane, Priya Kumthekar, & Jeffrey Raizer. (2013). Primary Central Nervous System Lymphoma. Current Treatment Options in Oncology. 14(2). 185–197. 12 indexed citations

12.

Doucet, Stéphane, Marie‐José Miron, Denis Soulières, et al.. (2007). D-DImer Dosing for Risk Prediction of Central Venous Catheter Thrombosis (The DIReCT Trial).. Blood. 110(11). 3980–3980. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact